573 related articles for article (PubMed ID: 29524515)
1. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?
Feduccia AA; Mithoefer MC
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):221-228. PubMed ID: 29524515
[TBL] [Abstract][Full Text] [Related]
2. Progress and promise for the MDMA drug development program.
Feduccia AA; Holland J; Mithoefer MC
Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674
[TBL] [Abstract][Full Text] [Related]
3. Potential Psychiatric Uses for MDMA.
Yazar-Klosinski BB; Mithoefer MC
Clin Pharmacol Ther; 2017 Feb; 101(2):194-196. PubMed ID: 27859039
[TBL] [Abstract][Full Text] [Related]
4. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale.
Johansen PØ; Krebs TS
J Psychopharmacol; 2009 Jun; 23(4):389-91. PubMed ID: 19273493
[TBL] [Abstract][Full Text] [Related]
5. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats.
Hake HS; Davis JKP; Wood RR; Tanner MK; Loetz EC; Sanchez A; Ostrovskyy M; Oleson EB; Grigsby J; Doblin R; Greenwood BN
Physiol Behav; 2019 Feb; 199():343-350. PubMed ID: 30529341
[TBL] [Abstract][Full Text] [Related]
6. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Mithoefer MC; Mithoefer AT; Feduccia AA; Jerome L; Wagner M; Wymer J; Holland J; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R
Lancet Psychiatry; 2018 Jun; 5(6):486-497. PubMed ID: 29728331
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).
Young MB; Norrholm SD; Khoury LM; Jovanovic T; Rauch SAM; Reiff CM; Dunlop BW; Rothbaum BO; Howell LL
Psychopharmacology (Berl); 2017 Oct; 234(19):2883-2895. PubMed ID: 28741031
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis.
Bahji A; Forsyth A; Groll D; Hawken ER
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109735. PubMed ID: 31437480
[TBL] [Abstract][Full Text] [Related]
9. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Mithoefer MC; Feduccia AA; Jerome L; Mithoefer A; Wagner M; Walsh Z; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R
Psychopharmacology (Berl); 2019 Sep; 236(9):2735-2745. PubMed ID: 31065731
[TBL] [Abstract][Full Text] [Related]
10. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD.
Brewerton TD; Lafrance A; Mithoefer MC
Med Hypotheses; 2021 Jan; 146():110367. PubMed ID: 33203569
[TBL] [Abstract][Full Text] [Related]
11. Fear extinction and memory reconsolidation as critical components in behavioral treatment for posttraumatic stress disorder and potential augmentation of these processes.
Smith NB; Doran JM; Sippel LM; Harpaz-Rotem I
Neurosci Lett; 2017 May; 649():170-175. PubMed ID: 28065842
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Jerome L; Feduccia AA; Wang JB; Hamilton S; Yazar-Klosinski B; Emerson A; Mithoefer MC; Doblin R
Psychopharmacology (Berl); 2020 Aug; 237(8):2485-2497. PubMed ID: 32500209
[TBL] [Abstract][Full Text] [Related]
13. Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.
Raut SB; Marathe PA; van Eijk L; Eri R; Ravindran M; Benedek DM; Ursano RJ; Canales JJ; Johnson LR
Pharmacol Ther; 2022 Nov; 239():108195. PubMed ID: 35489438
[TBL] [Abstract][Full Text] [Related]
14. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.
Amoroso T
J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955
[TBL] [Abstract][Full Text] [Related]
15. [MDMA-assisted therapy for PTSD].
Thorarinsdottir H; Gudmundsdottir B; Sigurdsson E
Laeknabladid; 2024 May; 110(5):254-261. PubMed ID: 38713560
[TBL] [Abstract][Full Text] [Related]
16. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis.
Illingworth BJ; Lewis DJ; Lambarth AT; Stocking K; Duffy JM; Jelen LA; Rucker JJ
J Psychopharmacol; 2021 May; 35(5):501-511. PubMed ID: 33345689
[TBL] [Abstract][Full Text] [Related]
17. MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics".
Sessa B
Neurosci Lett; 2017 May; 649():176-180. PubMed ID: 27394687
[TBL] [Abstract][Full Text] [Related]
18. Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: salience processing and fear inhibition processes.
Koch SB; van Zuiden M; Nawijn L; Frijling JL; Veltman DJ; Olff M
Psychoneuroendocrinology; 2014 Feb; 40():242-56. PubMed ID: 24485496
[TBL] [Abstract][Full Text] [Related]
19. Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.
Fattore L; Piva A; Zanda MT; Fumagalli G; Chiamulera C
Psychopharmacology (Berl); 2018 Feb; 235(2):433-445. PubMed ID: 29178010
[TBL] [Abstract][Full Text] [Related]
20. Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.
Szafoni S; Więckiewicz G; Pudlo R; Gorczyca P; Piegza M
Psychiatr Pol; 2022 Aug; 56(4):823-836. PubMed ID: 37074831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
